Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience

Table 2 Clinical outcomes of the study patients with early-stage uterine adenosarcoma who received uterine preservation therapy

Number	Age at diagnosis	Stage	Marital status^a	Primary therapy	SO	Adjuvant therapy	Recurrence	Time to recurrence, months	Disease status	F/U months	Event
1	33	IB	Single	HSC-mass excision	N	No	No		NED	12
2	33	IA	Single	HSC-mass excision	N	MPA 3 months	No		NED	77	Vaginal delivery
3	40	IA	Single	D/C/Bx	N	No	No		NED	32
4	21	IB	Single	HSC-mass excision	N	No	No		Persistent	17
5	22	IA	Single	Cx mass excision	N	No	No		Persistent	38
6	27	IA	Single	HSC-mass excision	Y	I/P#4	Yes	13	AWD	22	TAH c BSO d/t seeding
7	27	IB	Single	HSC-mass excision	N	No	Yes	27	AWD	38

^aStatus at diagnosis
SO sarcomatous overgrowth, F/U follow-up, HSC hysteroscopic, MPA medroxy progesterone acetate, D/C/Bx dilatation and curettage biopsy, Cx cervix, I/P ifosphamide/cisplatin, TAH c BSO total abdominal hysterectomy with bilateral salpingo-oophorectomy, d/t due to, NED no evidence of disease, AWD alive with disease

ISSN: 1477-7819